Introducing Idrasil™
The first standardized form of medical cannabis.
Founded
in 2010
Private
Ownership
Manufacturers
of Idrasil™
About us
C3® Pharmacueticals was formed to leverage first mover advantage and play a leadership role in the emergent cannabinoid therapeutics health sector. C3® is the manufacturer of the Idrasil™ Intellectual Property.
Research
Clinical EndoCannabinoid Deficiency (CECD)
Subsequent research has confirmed that underlying endocannabinoid deficiencies indeed play a role in migraine, fibromyalgia, irritable bowel syndrome, and a growing list of other medical conditions.
Common Uses
Migraine, Fibromyalgia and Irritable Bowel Syndrome
In a migraine, pathways involving serotonin are integral to the condition. THC (tetrahydrocannabinol) inhibits serotonin release from the blood platelets of humans with migraine headaches.5 Through a series of reactions involving ”anandamide” (AEA – the common name for arachidonylethanolamide – with behavioral activity similar to THC) both of these substances partially oppose CB1 receptors which are especially prevalent in the periaquaductal gray matter, the cerebral origin of most migraine headaches. 6 These and other observations suggest the probable efficacy of therapeutic cannabinoid in the treatment of a migraine.
